// App-Quantinova.ai

CTNI-43 : CXCL12 INHIBITION IN MGMT UNMETHYLATED GLIOBLASTOMA – RESULTS OF AN EARLY PROOF-OF-CONCEPT ASSESSMENT IN THE MULTICENTRIC PHASE I/II GLORIA TRIAL (NCT04121455)

Researchers

Presenter

  • Frank Giordano

Principal Investigators

  • Julian Layer

  • Sonia Leonardelli

  • Lea Friker

  • Clemens Seidel

  • Thomas Zeyen

  • Christina Schaub

  • Elena Sperk

  • Katharina Sahm

  • Sied Kebir

  • Peter Hambsch

  • Torsten Pietsch

  • Martin Glas

  • Sotirios Bisdas

  • Michael Holzel

  • Ulrich Herrlinger

Medical Centers

  • Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen, Essen, Nordrhein-Westfalen, Germany

  • Clinical Trial Unit, Mannheim Cancer Center, Medical Faculty, University of Heidelberg Mannheim, Mannheim, Germany

  • Institute of Experimental Oncology, Medical Faculty, University Hospital Bonn, Bonn, Germany

  • Department of Radiation Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany

  • Department of Urology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany

  • Department of Neuropathology, University Hospital Bonn, Bonn, Germany

  • Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, Bonn, Germany

  • Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany

  • Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust, London, UK

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • O-6-methylguanine DNA methyltransferase

  • Stromal cell-derived factor 1

  • Apparent diffusion coefficient

Drug/Treatment

  • NOX A12

  • CXCL12

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT04121455

Sponsors

  • NOXXON Pharma AG

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved